07.18.22
Roche has launched the Elecsys HCV Duo immunoassay in countries accepting the CE mark.
The immunoassay is the first for simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single plasma or serum sample. The test can be used to detect the infection’s early stage, as well as during recovery or hen there are signs of a chronic infection that could lead to other diseases like liver cancer.
Dual detection of HCV core antigen and antibodies means the Elecsys HCV Due assay can diagnose active hepatitis C earlier compared to antibody-only assays, because core antigen appears early in infection and is a marker of ongoing viral replication.
This can enable earlier intervention, reduced clinic visits for additional samples, and can alleviate some testing burden on healthcare systems.
“With improved hepatitis screening, healthcare systems have the opportunity to eliminate the disease through improved prevention, testing and treatment services,'' Thomas Schinecker, CEO of Roche Diagnostics told the press. “The addition of the Elecsys HCV Duo assay to our HCV testing portfolio can help in the fight to eliminate the hepatitis C virus. The launch of this innovative dual antigen and antibody diagnostic test underlines our commitment to support clinicians and their patients in reducing the impact of infectious diseases, where it’s needed most.”
The immunoassay is the first for simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status from a single plasma or serum sample. The test can be used to detect the infection’s early stage, as well as during recovery or hen there are signs of a chronic infection that could lead to other diseases like liver cancer.
Dual detection of HCV core antigen and antibodies means the Elecsys HCV Due assay can diagnose active hepatitis C earlier compared to antibody-only assays, because core antigen appears early in infection and is a marker of ongoing viral replication.
This can enable earlier intervention, reduced clinic visits for additional samples, and can alleviate some testing burden on healthcare systems.
“With improved hepatitis screening, healthcare systems have the opportunity to eliminate the disease through improved prevention, testing and treatment services,'' Thomas Schinecker, CEO of Roche Diagnostics told the press. “The addition of the Elecsys HCV Duo assay to our HCV testing portfolio can help in the fight to eliminate the hepatitis C virus. The launch of this innovative dual antigen and antibody diagnostic test underlines our commitment to support clinicians and their patients in reducing the impact of infectious diseases, where it’s needed most.”